A strategic executive treatment for executive dysfunction in patients with Parkinson’s disease

Not Applicable

Completed

• Conditions: Parkinson's disease; Nervous System Diseases; Parkinson disease

• Registration Number: ISRCTN13595005
• Lead Sponsor: Dutch Organization for Scientific Research (NWO), the National Initiative Brain and Cognition (NIHC)

Brief Summary

2020 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29566588 results (added 29/01/2019) 2017 Other publications in https://pubmed.ncbi.nlm.nih.gov/28427928/ (added 01/12/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2014-11-01
• Study Start: 2016-11-04
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Patients diagnosed with idiopathic Parkinson's disease according to the UK Parkinson’s Disease Brain Bank Criteria, with disease severity = Hoehn & Yahr (H&Y) stage 3
2. Age range 18-80 years
3. Patients had to be motivated for treatment
4. Patients had to report problems with EF in daily life that were experienced as burdensome (based on semi-structured interview and/or a total score of =18 on the Dysexecutive Questionnaire (DEX) and/or showed impairments on objective neuropsychological tests of executive function (EF):
4.1. A standard score of =2 on the subtests Zoo Map Test or Six Elements Test of the Behavioural Assessment of the Dysexecutive Syndrome (BADS) and/or
4.2. A standard age total score on the BADS categorized as low average” or lower and/or
4.3. A discrepancy of 15 points between standard age score and premorbid IQ as measured with the short version of the Dutch Groninger Intelligence Test
5. Patients had to speak and understand the Dutch language

Exclusion Criteria

1. Severe neurological comorbidity, such as traumatic brain injury or stroke
2. Severe psychiatric symptoms, such as hallucinations, delusions or depression
3. Severe cognitive comorbidity: e.g. amnestic syndrome, global aphasia, neglect, severe memory problems, PD dementia (i.e. SCales for Outcomes in PArkinson’s disease-COGnition scale score =17)
4. Hoehn & Yahr stage 4 and 5

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patients’ level of participation in different societal domains (i.e. work, social relations, leisure activities and mobility), measured using the Role Resumption list (RRL) at baseline, two weeks post-treatment and at 3-5 months follow-up